

There are 25 publications

- 1 A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.**  
A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Allen Ziegler, P. J. Stella, K. M. Rowland Jr, S. E. Schild, R. G. Zinner J Clin Oncol vol 26 (15s) abstr 8080 2008  
Abstract Respiratory  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=55&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID)
- 2 Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426**  
A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Ziegler, P. J. Stella, K. M. Rowland Jr, S. E. Schild, R. G. Zinner J Clin Oncol vol 28 (4) 614-619 2010  
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19841321>
- 3 A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9**  
D. L. Barton, B. Lavoie, J. A. Sloan, P. J. Stella, K. Flynn, M. Dyar, S. R. Dakhil, P. J. Atherton, B. Diekmann J Clin Oncol vol 26 (May 20 supplement) abstr 9538 2008  
Abstract Symptom Inter  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=55&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID)
- 4 Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2**  
D. L. Barton, H. Liu, S. R. Dakhil, B. Linnquist, J. A. Sloan, C. R. Nichols, T. W. Mcginn, P. J. Stella, G. R. Seeger, A. Sood, C. L. Loprinzi J Natl Cancer Inst vol 105 (15) 1230-8 2013  
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23853057>
- 5 A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).**  
G. K. Dy, S. J. Mandrekar, G. D. Nelson, H. J. Ross, R. H. Ansari, A. P. Lyss, P. J. Stella, S. E. Schild, J. R. Molina, A. A. Adjei J Clin Oncol vol 28 (15s) abstr 7603 2010  
Abstract Respiratory  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=74&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID)
- 6 Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C**  
A. Grothey, J. M. Lefky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen, W. S. Loui, B. M. Bot, S. R. Alberts, J. T. Reynolds J Clin Oncol vol 28 (15s) abstr 3549 2010  
Abstract GI <http://meetinglibrary.asco.org/content/51133-74>
- 7 N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy**  
T. J. Hobday, P. J. Stella, T. R. Fitch, A. Jaslowski, B. Laplant, M. M. Ames, M. P. Goetz, E. A. Perez J Clin Oncol vol 26 (May 20 suppl; abstr 1081) General Poster Session, Breast Cancer - Metastatic  
Abstract 1081 2008  
Abstract Breast  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=55&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID)
- 8 NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study**  
K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, J. N. Sarkaria, B. W.

Scheithauer, B. J. Erickson, J. C. Buckner J Clin Oncol vol 29 (suppl) abstr 2033 2011  
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/80655-102>

**9 Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials**

A. Jatoi, N. R. Foster, J. Egner, P. Burch, P. J. Stella, J. Rubin, S. R. Dakhil, D. J. Sargent, B. Murphy, S. R. Alberts J Clin Oncol vol 26 (15s abstr 9507) 503s 2008  
Abstract GI [http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15\\_suppl.9507](http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.9507)

**10 A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)**

A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Rowland Jr, P. J. Stella, G. S. Soori, A. A. Adjei Ann Oncol vol 21 (10) 2040-4 2010  
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20570832>

**11 Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer**

G. P. Kim, M. Haddock, N. R. Foster, J. Bollinger, P. J. Stella, J. W. Kugler, S. R. Alberts, J. Martenson J Clin Oncol vol 26 (15s) abstr 15553 2008  
Abstract GI

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=55&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID)

**12 Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib**

J. M. Lafky, S. K. Anderson, B. W. Morlan, G. D. Nelson, X. W. Carrero, S. Kumar, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis, A. Grothey Cancer Res vol 72 (8) abstr 5562 2012  
Abstract GI [http://cancerres.aacrjournals.org/content/72/8\\_Supplement/5562.short](http://cancerres.aacrjournals.org/content/72/8_Supplement/5562.short)

**13 Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib**

J. M. Lafky, B. M. Bot, B. W. Morlan, S. K. Anderson, S. K. Kumar, T. K. Kimlinger, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, A. Grothey J Clin Oncol vol 29 (suppl) abstr e14063 2011  
Abstract GI <http://meetinglibrary.asco.org/content/83471-102>

**14 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA**

C. L. Loprinzi, E. P. Balcueva, H. Liu, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Moore Jr, R. Zon, R. Levitt, J. A. Sloan J Clin Oncol vol 28 (15s) abstr 9024 2010  
Abstract Symptom Inter  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=74&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID)

**15 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment Group study N04CA**

C. L. Loprinzi, E. P. Balcueva, H. Liu, J. A. Sloan, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Moore Jr, R. T. Zon, R. Levitt, A. J. Jaslawski J Support Oncol vol 9 (3) 105-112 2011  
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21702402>

**16 Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology study**

C. L. Loprinzi, R. Qin, S. R. Dakhil, L. Fehrenbacher, P. J. Stella, P. Atherton, D. Seisler, R. Qamar,

G. C. Lewis, A. Grothey J Clin Oncol vol 31 (15 suppl) abstr 3501 2013  
Abstract Symptom Inter  
[http://meeting.ascopubs.org/cgi/content/abstract/31/15\\_suppl/3501?sid=afb15112-3f62-4e22-9fb1-e2c23](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3501?sid=afb15112-3f62-4e22-9fb1-e2c23)

**17 Pregabalin for hot flashes in women: NCCTG trial N07C1**

C. L. Loprinzi, R. Qin, P. J. Stella, K. M. Rowland Jr, D. L. Graham, N. Erwin, S. R. Dakhil, D. J. Jurgens, K. N. Burger J Clin Oncol vol 27 (15s) abstr 9513 2009  
Abstract Symptom Inter  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=65&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID)

**18 Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB**

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland Jr, P. L. Schaefer, J. E. Krook, J. Bearden, C. L. Loprinzi J Clin Oncol vol 28 (15s) abstr 9139 2010  
Abstract Symptom Inter  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=74&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID)

**19 Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB**

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland Jr, P. L. Schaefer, J. Krook, J. D. Bearden 3rd, C. L. Loprinzi J Support Oncol vol 8 (3) 128-132 2010  
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20552926>

**20 N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)**

A. Moreno-Aspitia, H. Liu, D. Hillman, K. M. Rowland Jr, X. Geiger, P. J. Stella, P. Kourlas, H. M. Gross, N. Karlin, M. J. Bury, G. S. Soori, A. Nassar, E. A. Perez J Clin Oncol vol 31 (15 suppl) abstr 1059 2013  
Abstract Breast <http://meetinglibrary.asco.org/content/115710-132>

**21 N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)**

A. Moreno-Aspitia, K. M. Rowland Jr, J. B. Allred, H. Liu, P. J. Stella, H. M. Gross, G. S. Soori, N. Karlin, E. A. Perez Cancer Res vol 72 (24 Suppl) P1-12-06 2012  
Abstract Breast [http://cancerres.aacrjournals.org/content/72/24\\_Supplement/P1-12-06.short](http://cancerres.aacrjournals.org/content/72/24_Supplement/P1-12-06.short)

**22 Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735**

D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Stella, P. J. Zander, M. K. Melnik, E. S. Pavey, E. A. Perez J Clin Oncol vol 29 (suppl) abstr 1126 2011  
Abstract Breast  
[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID)

**23 Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis**

S. E. Schild, N. R. Foster, J. P. Meyers, H. J. Ross, P. J. Stella, Y. I. Garces, K. R. Olivier, J. R. Molina, L. R. Past, A. A. Adjei Ann Oncol vol 23 (11) 2919-2924 2012  
Manuscript Respiratory NCCTG-86-20-51, NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-95-20-53 <http://www.ncbi.nlm.nih.gov/pubmed/22782333>

**24 Prognostic significance of baseline fatigue for overall survival: A patient-level meta-analysis of 43 oncology clinical trials with 3915 patients**

Jeff A. Sloan, H. Liu, D.V. Satele, S. Puttabasavaiah, J. S. Kaur, J. Hubbard, A. Dueck, P. J. Stella,

**25 N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer**

W. Tan, J. Allred, M. Salim, P. Flynn, J. W. Kugler, P. J. Stella, M. Wiesenfeld, A. M. Bernath Jr, T. R. Fitch, E. A. Perez J Clin Oncol vol 27 (15) abstr 120 2009

Abstract Breast

<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F1020>